Beta2-adrenergic activity modulates vascular tone regulation in lecithin: Cholesterol acyltransferase knockout mice

Vascular Pharmacology

Volumn 74, Issue , 2015, Pages 114-121

  Manzini, S ^a   Pinna, C ^a   Busnelli, M ^a   Cinquanta, P ^a   Rigamonti, E ^a   Ganzetti, G S ^a   Dellera, F ^a   Sala, A ^a,b   Calabresi, L ^a   Franceschini, G ^a   Parolini, C ^a   Chiesa, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b CNR   (Italy)

Author keywords

Adrenergic receptors; Aorta; Endothelial NO synthase; Lecithin:cholesterol acyltransferase; Mouse model

Indexed keywords

ACETYLCHOLINE; BETA 2 ADRENERGIC RECEPTOR; CHOLESTEROL ACYLTRANSFERASE; LIPOPROTEIN; N(G) NITROARGININE METHYL ESTER; NORADRENALIN; PROPRANOLOL; ADRENERGIC RECEPTOR STIMULATING AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ADRENERGIC ACTIVITY; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CONTROLLED STUDY; HUMAN; INVESTIGATIVE PROCEDURES; KNOCKOUT MOUSE; LCAT MOUSE; LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; MALE; MOUSE; MUSCLE CONTRACTILITY; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WILD TYPE; ANIMAL; C57BL MOUSE; DRUG EFFECTS; METABOLISM; VASODILATATION;

ADRENERGIC AGENTS; ANIMALS; AORTA; LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; LECITHINS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; RECEPTORS, ADRENERGIC, BETA-2; VASODILATION;

EID: 84947616759     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.08.006     Document Type: Article

References (36)

1. Jonas A. Lecithin cholesterol acyltransferase. Biochim. Biophys. Acta 2000, 1529:245-256. 10.1016/S1388-1981(00)00153-0.
2. Rousset X., Shamburek R., Vaisman B., et al. Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor?. Curr. Atheroscler. Rep. 2011, 13:249-256. 10.1007/s11883-011-0171-6.
3. Calabresi L., Simonelli S., Gomaraschi M., Franceschini G. Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease. Atherosclerosis 2012, 222:299-306. 10.1016/j.atherosclerosis.2011.11.034.
4. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 1977, 62:707-714.
5. Assmann G., Schulte H., von Eckardstein A., Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996, 124(Suppl.: S11-S20). 10.1016/0021-9150(96)05852-2.
6. Kuivenhoven J.A., Pritchard H., Hill J., Frohlich J., Assmann G., Kastelein J. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J. Lipid Res. 1997, 38:191-205.
7. Tietjen I., Hovingh G.K., Singaraja R., Radomski C., McEwen J., Chan E., et al. Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT. Biochim. Biophys. Acta 1821, 2012:416-424. 10.1016/j.bbalip.2011.08.006.
8. Kunnen S., Van Eck M. Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?. J. Lipid Res. 2012, 53:1783-1799. 10.1194/jlr.R024513.
9. Ayyobi A.F., McGladdery S.H., Chan S., John Mancini G.B., Hill J.S., Frohlich J.J. Lecithin:cholesterol acyltransferase (LCAT) deficiency and risk of vascular disease: 25year follow-up. Atherosclerosis 2004, 177:361-366. 10.1016/j.atherosclerosis.2004.07.018.
10. Hovingh G.K., Hutten B.A., Holleboom A.G., Petersen W., Rol P., Stalenhoef A., et al. Compromised LCAT function is associated with increased atherosclerosis. Circulation 2005, 112:879-884. 10.1161/CIRCULATIONAHA.105.540427.
11. Calabresi L., Baldassarre D., Castelnuovo S., Conca P., Bocchi L., Candini C., et al. Functional lecithin:cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation 2009, 120:628-635. 10.1161/CIRCULATIONAHA.108.818143.
12. Sakai N., Vaisman B.L., Koch C.A., Hoyt R.F., Meyn S.M., Talley G.D., et al. Targeted disruption of the mouse lecithin:cholesterol acyltransferase (LCAT) gene. Generation of a new animal model for human LCAT deficiency. J. Biol. Chem. 1997, 272:7506-7510. 10.1074/jbc.272.11.7506.
13. Ng D.S., Francone O.L., Forte T.M., Zhang J., Haghpassand M., Rubin E.M. Disruption of the murine lecithin:cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type I. J. Biol. Chem. 1997, 272:15777-15781. 10.1074/jbc.272.25.15777.
14. Ng D.S., Maguire G.F., Wylie J., Ravandi A., Xuan W., Ahmed Z., et al. Oxidative stress is markedly elevated in lecithin:cholesterol acyltransferase-deficient mice and is paradoxically reversed in the apolipoprotein E knockout background in association with a reduction in atherosclerosis. J. Biol. Chem. 2002, 277:11715-11720. 10.1074/jbc.M112320200.
15. Furbee J.W., Sawyer J.K., Parks J.S. Lecithin:cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice. J. Biol. Chem. 2002, 277:3511-3519. 10.1074/jbc.M109883200.
16. Calabresi L., Gomaraschi M., Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1724-1731. 10.1161/01.ATV.0000094961.74697.54.
17. Kratzer A., Giral H., Landmesser U. High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease. Cardiovasc. Res. 2014, 103:350-361. 10.1093/cvr/cvu139.
18. Luscher T.F., Landmesser U., von Eckardstein A., Fogelman A.M. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Cir. Res. 2014, 114:171-182. 10.1161/CIRCRESAHA.114.300935.
19. Calabresi L., Gomaraschi M., Simonelli S., Bernini F., Franceschini G. HDL and atherosclerosis: insights from inherited HDL disorders. Biochim. Biophys. Acta 1851, 2015:13-18. 10.1016/j.bbalip.2014.07.015.
20. Marchesi M., Parolini C., Caligari S., Gilio D., Manzini S., Busnelli M., et al. Rosuvastatin does not affect human apolipoprotein A-I expression in genetically modified mice: a clue to the disputed effect of statins on HDL. Br. J. Pharmacol. 2011, 164:1460-1468. 10.1111/j.1476-5381.2011.01429.x.
21. Carrier G.O., White R.E. Enhancement of alpha-1 and alpha-2 adrenergic agonist-induced vasoconstriction by removal of endothelium in rat aorta. J. Pharmacol. Exp. Ther. 1985, 232:682-687.
22. Alosachie I., Godfraind T. The modulatory role of vascular endothelium in the interaction of agonists and antagonists with alpha-adrenoceptors in the rat aorta. Br. J. Pharmacol. 1988, 95:619-629.
23. Topouzis S., Schott C., Stoclet J.C. Participation of endothelium-derived relaxing factor and role of cyclic GMP in inhibitory effects of endothelium on contractile responses elicited by alpha-adrenoceptor agonists in rat aorta. J. Cardiovasc. Pharmacol. 1991, 18:670-678.
24. Vanhoutte P.M. Endothelial adrenoceptors. J. Cardiovasc. Pharmacol. 2001, 38:796-808.
25. MacDonald A., McLean M., MacAulay L., Shaw A.M. Effects of propranolol and L-NAME on beta-adrenoceptor-mediated relaxation in rat carotid artery. J. Auton. Pharmacol. 1999, 19:145-149. 10.1046/j.1365-2680.1999.00128.x.
26. Tanaka Y., Horinouchi T., Koike K. New insights into beta-adrenoceptors in smooth muscle: distribution of receptor subtypes and molecular mechanisms triggering muscle relaxation. Clin. Exp. Pharmacol. Physiol. 2005, 32:503-514. 10.1111/j.1440-1681.2005.04222.x.
27. Chiesa G., Parolini C., Canavesi M., Colombo N., Sirtori C.R., Fumagalli R., et al. Human apolipoprotein A-I and A-II in cell cholesterol efflux: studies with transgenic mice. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1417-1423. 10.1161/01.ATV.18.9.1417.
28. Khurana S., Chacon I., Xie G., Yamada M., Wess J., Raufman J.P., et al. Vasodilatory effects of cholinergic agonists are greatly diminished in aorta from M3R-/- mice. Eur. J. Pharmacol. 2004, 493:127-132. 10.1016/j.ejphar.2004.04.012.
29. Yuhanna I.S., Zhu Y., Cox B.E., Hahner L.D., Osborne-Lawrence S., Lu P., et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 2001, 7:853-857. 10.1038/89986.
30. Nofer J.R., van der Giet M., Tolle M., Wolinska I., von Wnuck Lipinski K., Baba H.A., et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 2004, 113:569-581. 10.1172/JCI18004.
31. Mineo C., Yuhanna I.S., Quon M.J., Shaul P.W. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J. Biol. Chem. 2003, 278:9142-9149. 10.1074/jbc.M211394200.
32. Gonzales E., Kou R., Michel T. Rac1 modulates sphingosine 1-phosphate-mediated activation of phosphoinositide 3-kinase/Akt signaling pathways in vascular endothelial cells. J. Biol. Chem. 2006, 281:3210-3216. 10.1074/jbc.M510434200.
33. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999, 399:597-601. 10.1038/21218.
34. Zou M.H., Shi C., Cohen R.A. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J. Clin. Invest. 2002, 109:817-826. 10.1172/JCI14442.
35. Landmesser U., Dikalov S., Price S.R., McCann L., Fukai T., Holland S.M., et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest. 2003, 111:1201-1209. 10.1172/JCI14172.
36. Forstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch. - Eur. J. Physiol. 2010, 459:923-939. 10.1007/s00424-010-0808-2.